493 related articles for article (PubMed ID: 12798639)
21. Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses.
Marinaro M; Fasano A; De Magistris MT
Infect Immun; 2003 Apr; 71(4):1897-902. PubMed ID: 12654806
[TBL] [Abstract][Full Text] [Related]
22. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.
Romeu B; González E; Del Campo J; Acevedo R; Zayas C; Valdés Y; Cabrera O; Cuello M; Balboa J; Lastre M; Pérez O
Can J Microbiol; 2011 Mar; 57(3):256-61. PubMed ID: 21358768
[TBL] [Abstract][Full Text] [Related]
23. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
[TBL] [Abstract][Full Text] [Related]
24. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.
Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K
J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339
[TBL] [Abstract][Full Text] [Related]
25. Oral vaccine models: multiple delivery systems employing tetanus toxoid.
Jackson RJ; Staats HF; Xu-Amano J; Takahashi I; Kiyono H; Hudson ME; Gilley RM; Chatfield SN; McGhee JR
Ann N Y Acad Sci; 1994 Aug; 730():217-34. PubMed ID: 8080173
[TBL] [Abstract][Full Text] [Related]
26. Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit.
Kubota E; Joh T; Tanida S; Sasaki M; Kataoka H; Watanabe K; Itoh K; Oshima T; Ogasawara N; Togawa S; Wada T; Yamada T; Mori Y; Fujita F; Shimura T; Ohara H; Isaka M; Yasuda Y; Itoh M
Helicobacter; 2005 Aug; 10(4):345-52. PubMed ID: 16104951
[TBL] [Abstract][Full Text] [Related]
27. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens.
Klinguer C; Beck A; De-Lys P; Bussat MC; Blaecke A; Derouet F; Bonnefoy JY; Nguyen TN; Corvaïa N; Velin D
Vaccine; 2001 Jul; 19(30):4236-44. PubMed ID: 11457550
[TBL] [Abstract][Full Text] [Related]
28. Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid.
Bergquist C; Lagergård T; Holmgren J
APMIS; 1998 Aug; 106(8):800-6. PubMed ID: 9744766
[TBL] [Abstract][Full Text] [Related]
29. Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines.
Klein K; Mann JF; Rogers P; Shattock RJ
J Control Release; 2014 Jun; 183():43-50. PubMed ID: 24657807
[TBL] [Abstract][Full Text] [Related]
30. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.
Ohmura M; Yamamoto M; Kiyono H; Fujihashi K; Takeda Y; McGhee JR
Vaccine; 2001 Dec; 20(5-6):756-62. PubMed ID: 11738739
[TBL] [Abstract][Full Text] [Related]
31. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
McNeela EA; O'Connor D; Jabbal-Gill I; Illum L; Davis SS; Pizza M; Peppoloni S; Rappuoli R; Mills KH
Vaccine; 2000 Dec; 19(9-10):1188-98. PubMed ID: 11137256
[TBL] [Abstract][Full Text] [Related]
32. Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres.
Gupta RK; Griffin P; Rivera R; Siber GR
Dev Biol Stand; 1998; 92():277-87. PubMed ID: 9554282
[TBL] [Abstract][Full Text] [Related]
33. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
[TBL] [Abstract][Full Text] [Related]
34. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum.
Grangette C; Müller-Alouf H; Goudercourt D; Geoffroy MC; Turneer M; Mercenier A
Infect Immun; 2001 Mar; 69(3):1547-53. PubMed ID: 11179325
[TBL] [Abstract][Full Text] [Related]
35. Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions.
Ekström J; Hu KF; Bengtsson KL; Morein B
Vaccine; 1999 Jun; 17(20-21):2690-701. PubMed ID: 10418920
[TBL] [Abstract][Full Text] [Related]
36. Immunological response of recombinant H. pylori multi-epitope vaccine with different vaccination strategies.
Wang B; Pan X; Wang H; Zhou Y; Zhu J; Yang J; Li W
Int J Clin Exp Pathol; 2014; 7(10):6559-66. PubMed ID: 25400734
[TBL] [Abstract][Full Text] [Related]
37. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine.
Hall ER; Wierzba TF; Ahrén C; Rao MR; Bassily S; Francis W; Girgis FY; Safwat M; Lee YJ; Svennerholm AM; Clemens JD; Savarino SJ
Infect Immun; 2001 May; 69(5):2853-7. PubMed ID: 11292698
[TBL] [Abstract][Full Text] [Related]
38. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.
Kozlowski PA; Williams SB; Lynch RM; Flanigan TP; Patterson RR; Cu-Uvin S; Neutra MR
J Immunol; 2002 Jul; 169(1):566-74. PubMed ID: 12077289
[TBL] [Abstract][Full Text] [Related]
39. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.
Blanchard TG; Lycke N; Czinn SJ; Nedrud JG
Immunology; 1998 May; 94(1):22-7. PubMed ID: 9708182
[TBL] [Abstract][Full Text] [Related]
40. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
